A Phase 3 interventional study of Ampicillin/Sulbactam 24-Hour Postoperative Prophylaxis and Ampicillin/Sulbactam 7-Day Postoperative Prophylaxis in Surgical Wound Infection, Head and Neck Neoplasms and Oral Cancer Neoplasms, sponsored by AC Camargo Cancer Center. Recruiting at 1 site in Brazil. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-05.
Sponsored by AC Camargo Cancer Center · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 15 studies in Surgical Wound Infection with a site in Brazil — 2 open to participants now, 2 under way, 2 of them phase 3. Surgical Wound Infection · Brazil.
Among the 15 studies in Surgical Wound Infection with a site in Brazil, this one is the 11th largest by planned enrollment, is the only one that started in 2025, is one of 5 in phase 3, and was the 15th registered.
747 studies on the registry are indexed under Surgical Wound Infection; 152 are open to participants now.
Browse Surgical Wound Infection studies →2 of the 15 studies in Surgical Wound Infection with a site in Brazil are open now. Recruiting first, the newest first:
Hospital de Clinicas de Porto Alegre · Sites in Brazil
Ages 18+
A study can be open while its sites in Brazil have not opened yet or have stopped. Only those recruiting at a site in Brazil →
Of the 85 Surgical Wound Infection studies recruiting now, 62 (73%) set no upper age limit and 16 (19%) stop at 75 or younger; 12 take children under 18; 14 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
15 studies; the count open now beside each. This study's row is marked.
First in 2007; this study’s year is marked. 1 started in 2025.
This study's planned enrollment of 80 is below the median of 200 across 583 interventional studies indexed under Surgical Wound Infection.
Median enrollment 124 across the 15 interventional studies. Of the 12 that completed or were terminated, 2 (17%) have results posted.
This tab as a report to print or save as PDF → With an account.
2 of 15 have an industry lead sponsor. The 10 most frequent:
AC Camargo Cancer Center is the lead sponsor of 28 studies on the registry; 9 are open to participants now.
AC Camargo Cancer Center has 1 study filed under Surgical Wound Infection — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 15 studies in Surgical Wound Infection with a site in Brazil, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this clinical trial is to learn whether giving antibiotics for 7 days after surgery, instead of the usual 24 hours, lowers the chance of wound infection in adults having major surgery for mouth or throat cancer. This includes operations that rebuild the area with tissue taken from another part of the body (free-flap reconstruction).
The main question it aims to answer is:
Does a 7-day course of antibiotics after surgery lower the number of patients who get a surgical wound infection within 30 days, compared with the standard 24-hour course?
Other questions are:
Does the longer course shorten the time spent in the intensive care unit and in the hospital? Does it lower the number of emergency room visits, hospital readmissions, and hospital costs within 30 days? Is the longer course safe, and does it cause more side effects?
Researchers will compare two groups. Both groups receive the same antibiotic (ampicillin/sulbactam) through a vein before and during surgery. After surgery, one group continues the antibiotic for 24 hours (the current standard), and the other group continues it for 7 days, or until they go home if that is sooner.
Participants will:
Be assigned by chance (like flipping a coin) to one of the two groups Follow the hospital's usual care before surgery, including mouthwash, antiseptic body wash, and nasal ointment for 5 days Receive the antibiotic according to their group Be followed for 30 days after surgery to check for wound infection, other complications, return visits, and readmissions
Background and Rationale
Surgical site infection (SSI) is a common and serious complication of major head and neck cancer surgery. Operations such as mandibulectomy, pharyngolaryngectomy, and major glossectomy, and procedures that need microvascular free-flap or pedicled flap reconstruction, expose the neck to bacteria from the oral cavity and upper aerodigestive tract for many hours. Several other factors add to the risk: tumor-associated oral dysbiosis, long operative times, flap ischemia, dead space, previous radiotherapy, malnutrition, tobacco and alcohol use, and tracheostomy. As a result, reported SSI rates in these operations range from 20% to 50%. That is much higher than expected for clean-contaminated procedures and closer to the rates seen in infected procedures. SSI is linked to fistula, flap failure, reoperation, longer hospital stays, delays in adjuvant treatment, and higher costs.
Centers for Disease Control and Prevention (CDC) and World Health Organization (WHO) guidelines advise against continuing antibiotic prophylaxis after surgery ends. However, these guidelines do not address the specific risk factors of head and neck reconstruction, and these patients are underrepresented in the trials behind them. Practice varies widely: in one survey of microvascular surgeons, 5 days of prophylaxis was the most common duration, and some authors recommend 7 days for free-flap cases. Retrospective studies disagree about whether longer courses help, and no randomized evidence exists. Data from low- and middle-income countries, where SSI rates are higher, are especially limited.
At the study institution, SSI indicators have been collected prospectively since 2014. SSI rates in major and free-flap head and neck procedures stayed between 33% and 50.9%. This was true even after the prophylactic regimen was changed from clindamicin plus ceftriaxone to ampicillin/sulbactam in 2022, and after a preoperative decolonization protocol was introduced. In a previous prospective cohort of 401 patients, the overall SSI rate was 41.9%. This trial tests whether extending postoperative prophylaxis lowers SSI and length of stay in this high-risk group.
Study Design
Single-center, pragmatic, open-label, randomized, parallel-group superiority trial. The trial is pragmatic because both regimens are already used in clinical practice. Blinding is not feasible because the arms differ in how long the postoperative antibiotic is given.
Randomization
Patients are allocated 1:1 using a maximum tolerated imbalance (MTI) procedure with an imbalance limit of 3. When the limit is reached, the next patient is assigned to the smaller arm. This lowers the predictability of allocation while keeping the arms balanced. Allocation is generated dynamically in REDCap after enrollment, and patients do not cross over between arms.
Standardized Perioperative Care (Both Arms)
Preoperative decolonization for 5 days: 0.12% chlorhexidine oral rinse three times a day, 2% chlorhexidine body wash once a day, and nasal mupirocin three times a day.
Preoperative consultations with nursing, nutrition (with supplementation when needed), and oral medicine.
In the operating room: 2-minute skin antisepsis of the resection and donor sites with 2% chlorhexidine or 10% povidone-iodine, plus oral and pharyngeal cleansing with 0.12% chlorhexidine.
The first antibiotic dose is given at anesthesia induction, 10 to 60 minutes before skin incision, and redosed every 4 hours during surgery.
Data Collection
Data are collected from the electronic medical record with a standardized case report form and entered in REDCap. Variables include:
Demographics and lifestyle: age, sex, smoking (pack-years), alcohol use. Clinical data: comorbidities, American Society of Anesthesiologists Physical Status Classification System, Body Mass Index.
Tumor data: site, histology, UICC-TNM stage, prior radiotherapy or chemotherapy.
Surgical data: main procedure, type of reconstruction, flap ischemia time (from pedicle ligation to completion of the anastomoses), operative time (from skin incision to dressing), salvage surgery, and perioperative blood transfusion.
Cost Analysis
Costs are taken from the institution's patient-level billing database (Base de Atendimento) for the index surgical admission. Direct costs are materials, drugs, and professional fees. Indirect costs are allocated by absorption costing and include idle capacity. The analysis follows the Brazilian Ministry of Health guidelines for economic evaluation, takes the payer perspective, and uses micro-costing. Unit prices come from public procurement references: BEC/SP and the Ministry of Health Health Price Database.
Statistical Analysis
Analyses follow the intention-to-treat principle and are done in R and Python. Categorical variables are compared with the chi-square test and continuous variables with Student's t-test. Multivariable analysis uses Cox proportional hazards models, with the proportional hazards assumption checked by Schoenfeld residuals.
Sample Size The sample size was calculated for the primary outcome (30-day SSI) as a comparison of two independent proportions. The SSI rate in the control group was assumed to be 43%, based on the institutional prospective cohort of patients undergoing major head and neck surgery. An SSI rate of 12% was expected in the intervention group, which is an absolute reduction of 31 percentage points.
With a two-sided significance level of 5% and 80% power, at least 32 evaluable patients per group are needed. Allowing for an estimated 10% loss to follow-up, the sample was set at 40 patients per group, for a total of 80 participants. The calculation was done in G*Power, version 3.1.9.7.
Interim Safety Analysis
A safety analysis will be done once 50% of the planned patients have completed 30 days of follow-up. Adverse events are graded using CTCAE. The two arms will be compared for serious treatment-related complications, including infections other than SSI (such as Clostridioides difficile), drug toxicity, and allergic reactions. If the difference in serious adverse event rates between the arms is greater than 20%, early termination or protocol changes will be considered together with the institutional Infection Prevention and Control Service.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants receive the institutional standard antibiotic prophylaxis with ampicillin/sulbactam: 3 g IV at anesthesia induction (10 to 60 minutes before skin incision), 3 g IV every 4 hours during surgery, and 3 g IV every 6 hours for 24 hours after surgery. All participants also complete the institutional preoperative decolonization protocol for 5 days before surgery (chlorhexidine oral rinse, chlorhexidine body wash, and nasal mupirocin).
Drug: Ampicillin/Sulbactam 24-Hour Postoperative Prophylaxis
Participants receive ampicillin/sulbactam 3 g IV at anesthesia induction (10 to 60 minutes before skin incision) and 3 g IV every 4 hours during surgery, the same as the standard group. After surgery, the antibiotic continues at 3 g IV every 6 hours for 7 days, or until hospital discharge if that is sooner. All participants also complete the institutional preoperative decolonization protocol for 5 days before surgery (chlorhexidine oral rinse, chlorhexidine body wash, and nasal mupirocin). Interventions: ☑ Ampicillin/Sulbactam 7-Day Postoperative Prophylaxis
Drug: Ampicillin/Sulbactam 7-Day Postoperative Prophylaxis
Participants receive the institutional standard antibiotic prophylaxis with ampicillin/sulbactam: 3 g IV at anesthesia induction (10 to 60 minutes before skin incision), 3 g IV every 4 hours during surgery, and 3 g IV every 6 hours for 24 hours after surgery. All participants also complete the institutional preoperative decolonization protocol for 5 days before surgery (chlorhexidine oral rinse, chlorhexidine body wash, and nasal mupirocin).
Participants receive ampicillin/sulbactam 3 g IV at anesthesia induction (10 to 60 minutes before skin incision) and 3 g IV every 4 hours during surgery, the same as the standard group. After surgery, the antibiotic continues at 3 g IV every 6 hours for 7 days, or until hospital discharge if that is sooner. All participants also complete the institutional preoperative decolonization protocol for 5 days before surgery (chlorhexidine oral rinse, chlorhexidine body wash, and nasal mupirocin).
Incidence of Surgical Site Infection
Proportion of participants in each arm who develop a surgical site infection (SSI) within 30 days after surgery. SSI is diagnosed when at least one of the following is present: (1) purulent drainage from the incision; (2) a positive culture from fluid or tissue at the incision obtained with aseptic technique; or (3) a diagnosis of SSI by the attending surgeon or physician. The groups are compared using the chi-square test (intention-to-treat analysis).
Time frame: From surgery through postoperative day 30
Secondary Outcome Measure [*]
Number of days the participant stays in the intensive care unit (ICU) during the surgical admission.
Time frame: From surgery through hospital discharge, up to 30 days after surgery
Hospital Length of Stay
Number of days from hospital admission for surgery to hospital discharge.
Time frame: From hospital admission through discharge, up to 30 days after surgery
Hospital Readmission Rate
Proportion of participants readmitted to the hospital for clinical or surgical complications within 30 days after discharge from the surgical admission. Planned admissions for adjuvant treatment (such as placement of a chemotherapy catheter) are not counted.
Time frame: Within 30 days after hospital discharge
Emergency Department Visit Rate
Proportion of participants who make at least one unscheduled emergency department visit after discharge from the surgical admission.
Time frame: Within 30 days after surgery
Total Hospitalization Cost
Total cost of the surgical admission, in Brazilian reais (BRL), including direct costs (materials, drugs, professional fees) and indirect costs (allocated by absorption costing). Micro-costing is used, from the payer perspective.
Time frame: From hospital admission through discharge, up to 30 days after surgery
Incidence of Serious Adverse Events
Proportion of participants with serious treatment-related adverse events, graded using the Common Terminology Criteria for Adverse Events (CTCAE). These include infections other than SSI (for example Clostridioides difficile infection or pneumonia), allergic reactions, acute kidney injury, and other antibiotic-related toxicity.
Time frame: From surgery through postoperative day 30
Plan to share: Yes — De-identified individual participant data underlying the published results (the primary and secondary outcomes) will be shared on reasonable request. Data will be anonymized according to the Brazilian General Data Protection Law (LGPD) before release.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Time frame: Beginning 6 months after publication of the primary results and ending 5 years after publication.
Access criteria: Data will be available to qualified researchers who submit a methodologically sound proposal, which the principal investigator will review. A data use agreement will be required, as well as approval from the A.C. Camargo Cancer Center Research Ethics Committee when applicable. Requests should be sent to the principal investigator.
Ran from May 2025 to primary completion in Jun 2025, 1 month.
Of 38 phase 3 interventional studies under Surgical Wound Infection, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 51. This study's 1 month is below that.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
AC Camargo Cancer Center